Effects of Oral Administration of Type II Collagen on Rheumatoid Arthritis

DOI Web Site 被引用文献24件
  • David E. Trentham
    Division of Rheumatology, Department of Medicine, Beth Israel Hospital, the Charles A. Dana Research Institute, the Harvard-Thorndike Laboratory, Harvard Medical School, Boston, MA 02215.
  • Roselynn A. Dynesius-Trentham
    Division of Rheumatology, Department of Medicine, Beth Israel Hospital, the Charles A. Dana Research Institute, the Harvard-Thorndike Laboratory, Harvard Medical School, Boston, MA 02215.
  • E. John Orav
    Department of Medicine, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA 02115.
  • Daniel Combitchi
    Division of Rheumatology, Department of Medicine, Beth Israel Hospital, the Charles A. Dana Research Institute, the Harvard-Thorndike Laboratory, Harvard Medical School, Boston, MA 02215.
  • Carlos Lorenzo
    Division of Rheumatology, Department of Medicine, Beth Israel Hospital, the Charles A. Dana Research Institute, the Harvard-Thorndike Laboratory, Harvard Medical School, Boston, MA 02215.
  • Kathryn Lea Sewell
    Division of Rheumatology, Department of Medicine, Beth Israel Hospital, the Charles A. Dana Research Institute, the Harvard-Thorndike Laboratory, Harvard Medical School, Boston, MA 02215.
  • David A. Hafler
    Center for Neurologic Diseases, Division of Neurology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
  • Howard L. Weiner
    Center for Neurologic Diseases, Division of Neurology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.

書誌事項

公開日
1993-09-24
DOI
  • 10.1126/science.8378772
公開者
American Association for the Advancement of Science (AAAS)

この論文をさがす

説明

<jats:p>Rheumatoid arthritis is an inflammatory synovial disease thought to involve T cells reacting to an antigen within the joint. Type II collagen is the major protein in articular cartilage and is a potential autoantigen in this disease. Oral tolerization to autoantigens suppresses animal models of T cell-mediated autoimmune disease, including two models of rheumatoid arthritis. In this randomized, double-blind trial involving 60 patients with severe, active rheumatoid arthritis, a decrease in the number of swollen joints and tender joints occurred in subjects fed chicken type II collagen for 3 months but not in those that received a placebo. Four patients in the collagen group had complete remission of the disease. No side effects were evident. These data demonstrate clinical efficacy of an oral tolerization approach for rheumatoid arthritis.</jats:p>

収録刊行物

  • Science

    Science 261 (5129), 1727-1730, 1993-09-24

    American Association for the Advancement of Science (AAAS)

被引用文献 (24)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ